THE INTERRELATION OF CYP2C9, CYP4F2, VKORC1 GENES POLYMORPHISMS  WITH WARFARIN DOSE AND HEMORRHAGIC COMPLICATIONS RISK RISE IN PATIENTS  WITH ATRIAL FIBRILLATION: A RETROSPECTIVE STUDY

M.  Kolesnyk; Y.  Mykhailovskyi

Авторы

M. Kolesnyk Запорожский государственный медицинский университет
Y. Mykhailovskyi Запорожский государственный медицинский университет

Ключевые слова:

фибрилляция предсердий, варфарин, дозировка, гены, кровотечение.

Аннотация

Целью исследования было выявить частоту полиморфизмов генов CYP2C9, CYP4F2, VKORC1 у пациентов с фибрилляцией предсердий (ФП) и установить их взаимосвязь с дозой варфарина (ВФ) и повышением риска геморрагических осложнений.

Биографии авторов

M. Kolesnyk, Запорожский государственный медицинский университет

д.мед.н., профессор, профессор кафедры семейной медицины, терапии и кардиологии факультета последипломного образования

Y. Mykhailovskyi , Запорожский государственный медицинский университет

PhD-аспирант кафедры семейной медицины, терапии и кардиологии факультета последипломного образования

Библиографические ссылки

Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017 Mar; 14(3): 195-203. DOI: 10.11909/j.issn.1671-5411.2017.03.011

Sankaranarayanan R., Kirkwood G., Visweswariah R., Fox D.J. How does Chronic Atrial Fibrillation Influence Mortality in the Modern

Treatment Era? Curr Cardiol Rev. 2015 Aug;11(3):190–198. https://doi.org/10.2174/1573403X10666140902143020 3. Sychov OS, Borodai AO, Borodai ES. Predictors of cardiovascular outcomes in patients with non-valvular atrial fibrillation and flutter. Ukrainskyi kardiolohichnyi zhurnal. 2016;6:64-75. (in Ukr.).

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. https://doi.org/10.1136/bmjopen-2017-017157

Tseluyko VI, Opolonskaya NA. The Prevalence of Risk Factors for Thromboembolic and Hemorrhagic Complications among Patients with Atrial Fibrillation. Medicyna neotlozhnykh sostoyanij. 2013;7(54):65-69. (in Russ.).

Oladirana O, Nwosub I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect. 2019 Apr;9(2):113-120. https://doi.org/10.1080/20009666.2019.1593781

Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975–2983. https://doi.org/10.1093/eurheartj/ehy411.

Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and preferences of physicians and patients with Nonvalvular atrial fibrillation who receive Oral anticoagulation therapy for stroke prevention. Can J Cardiol. 2016;32(6):747–53. https://doi.org/10.1016/j.cjca.2015.09.023

Kropacheva ES, Borovkov NN, Vavilova TV, Verenina NK, Vorob’eva NA, Galkina IS, et al. The rapid pace of saturation of warfarin - a predictor of excessive anticoagulation. Modernization algorithm dose adjustment of warfarin. Aterotromboz. 2015;1:7586. (in Russ.).

Bader LA, Elewa H. The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. PLoS One. 2016;11(12):e0168732. https://doi.org/10.1371/journal.pone.0168732

Geoffrey SG, Huntington FW, editors. Genomic and Precision Medicine: Cardiovascular Disease, Third Edition. Academic Press; 2017. Chapter 16, Cardiovascular Pharmacogenetics. р.291-307. https://doi.org/10.1016/C2015-0-06899-X

Francis Lam YW, Scott SA, editors. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation, Second Edition. Academic Press; 2019. Chapter 6, Pharmacogenetics in Cardiovascular Diseases. р. 133-179. https://doi.org/10.1016/C2016-0-03878-0

Sychov OS, Borodai ES, Borodai AO. Recommendations for the use of pharmacogenetic testing in clinical practice. Ukrainian Journal of Cardiology. 2016;6:64–75 (in Russ).

Jorgensen AL, Richard J, Gerald F, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLoS One. 2012;7(8):e44064. https://doi.org/10.1371/journal.pone.0044064.

Sun X, Yu W-Y, Ma W-L, Huang L-H, Yang G-P. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomed Rep. 2016 Apr;4(4):498–506. https://doi.org/10.3892/br.2016.599

Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet. 2010 Sep;55(9):582-9. https://doi.org/10.1038/jhg.2010.73.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678. https://doi.org/10.1093/europace/euw295

Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69:236-239. DOI: 10.1055/s-0038-1651587

Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Annal of Internal Medicine. 1993;118(7):511–520. DOI: 10.7326/0003-4819-118-7-199304010-00005

Buzoianu AD, Trifa AP, Mureşanu DF, Crişand S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med. 2012 Dec ;16(12):2919–2924. https://doi.org/10.1111/j.1582-4934.2012.01606.x

Levkovich NM, Gorovenko NG. Allele frequency distribution of CYP2C9 gene in Ukrainian population. Odeskyi medychnyi zhurnal. 2013;2:23-28. (in Ukr.).

Zhang J, Chen Z, Chen C. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. Meta Gene. 2016 Jul; 9:197-209. DOI: 10.1016/j.

Tomek A, Maťoška V, Kolářová T, Neumann J, Šrámek M, Šarbochová I., et al. The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes. Cardiology. 2013;125:182-191.https://doi.org/10.1159/000350407